Arming oncolytic viruses with ICBs by encoding checkpoint inhibitors or antibodies to block PD-L1 or CTLA-4 within the virus itself may yield comparable or even better anti-tumor activity compared to combinations of an oncolytic virus and ICBs. This evidence concerns the gene CTLA4 and neoplasm.